Updates

Quantum Pharma

September 2015

Investing in shares may lose you all or some of your money. Past performance is no indication of future performance. Some of the shares recommended here may be small company shares, which can be relatively illiquid and hard to trade and this makes such shares more risky than other investments.

The shares came off after Quantum’s H1 trading update, despite the company saying that full year results are in-line and forecasts are unchanged.The Colonis pipeline currently has 16 products with the MHRA awaiting registration. Two products have so far launched, with a third expected to launch this month and 11 are expected to launch by the end of the year. The reason for the drop in the share price is that 17 approved drugs had been expected by then so it seems that regulatory approval for six of them has taken a bit longer to come through. But none have been rejected and all six are expected to come through next year. But there is also a silver lining because the pipeline is building up with 70 products in development ...

To access our archive of articles and to receive current issues you need to subscribe.

Subscribe now

Already a subscriber? Login

Kainos

Cohort - Eps enhancing deal in Portugal; gain since January 58%

Quantum Pharma - Gain since our February write up: 75% (October 2017)

Quantum Pharma - Bid from Clinigen (September 2017)

Quantum Pharma (June 2017)

Quantum Pharma - Considerably less flannel from new CEO (February 2017)

Quantum Pharma - Sweep of board and placing (November 2016)

Quantum Pharma (June 2016)

Quantum Pharma (March 2016)

Quantum Pharma - Five more products now approved (November 2015)

Quantum Pharma - Soon-to-be prospective PE of 9.9 (October 2015)

Quantum Pharma - Explosive growth trajectory (June 2015)

With small companies there is an above average degree of risk compared to buying blue chips. Please be aware that we have not assessed the suitability of any of these investments for you. The newsletter simply states a personal view and diarises the editor’s investment decisions. Please speak to your stockbroker or other qualified individual to ascertain whether any of these companies mentioned would form useful additions to your own portfolios. Past performance is no indication of future success.

All material on this website is protected by copyright. You may use Information retrieved from the www.scsw.co.uk website for your own personal non-commercial use which means that you may not sell or copy this information to any third party without prior written consent. ISSN 1358-183X